• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Uterine Cancer - Pipeline Review, Q2 2011 - Product Image

Uterine Cancer - Pipeline Review, Q2 2011

  • Published: April 2011
  • 139 pages
  • Global Markets Direct

Uterine Cancer - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Uterine Cancer - Pipeline Review, Q2 2011', provides an overview of the Uterine Cancer therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. 'Uterine Cancer - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Uterine Cancer.
- A review of the Uterine Cancer products under development by companies and universities/research institutes based on information READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Uterine Cancer
Uterine Cancer Therapeutics under Development by Companies
Uterine Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Uterine Cancer Therapeutics - Products under Development by Companies
Uterine Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Uterine Cancer Therapeutics Development
Bristol-Myers Squibb Company
Sanofi-Aventis
InterMed Discovery GmbH
Tigris Pharmaceuticals, Inc.
Uterine Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Yervoy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BSI-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMD-026260 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lonafarnib + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trabectedin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec + Taxol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin + Gemcitabine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Zactima - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vorinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atengenal + Astugenal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Filgrastim + Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GW786034 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aflibercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Gemcitabine + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Javlor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E7389 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iressa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ixabepilone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hycamtin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel + Bevacizumab + Filgrastim + Pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel + Filgrastim + Pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-247550 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxol + Paraplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + Taxol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BSI-201 + Paraplatin/Taxol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ifosfamide + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Carboplatin + BSI-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-007_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pemetrexed + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PS-341 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Carboplatin + Megesterol Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel + Adiramycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Ifosfamide + Mesna - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Gemcitabine + Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irinotecan + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Vinorelbine Ditartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irinotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irinotecan + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Gemcitabine + Vandetanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Ifosfamide + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Ifosfamide + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel, Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Methotrexate + Vinblastine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Gemcitabine + Lapatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arimidex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel + Radiation Theraphy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin Hydrochloride + Mitomycin C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Gemcitabine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Gemcitabine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Paclitaxel + Doxorubicin + Pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pazopanib Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sargramostim + Cisplatin + Dacarbazine + Doxorubicin Hydrochloride + Mitomycin C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uterine Cancer Therapeutics – Drug Profile Updates
Uterine Cancer Therapeutics - Discontinued Products
Uterine Cancer - Featured News
May 28, 2008: BiPar Sciences Expands Clinical Development Of BSI-201, A Novel PARP Inhibitor, With Phase II Trial In Uterine Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Uterine Cancer, Q2 2011
Products under Development for Uterine Cancer – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Bristol-Myers Squibb Company, 2011
Sanofi-Aventis, 2011
InterMed Discovery GmbH, 2011
Tigris Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Uterine Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Uterine Cancer, Q2 2011
Products under Development for Uterine Cancer – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos